Participated · Seed · May 2026

Urologic Health is developing the niu™ System, a non-invasive platform designed to capture bladder activity and convert it into clinically meaningful diagnostic data without catheterization. The company has completed early feasibility studies that it says demonstrate clinically meaningful capture of bladder activity and is pursuing an FDA 510(k) regulatory pathway. The niu™ System is not yet approved for sale in the United States and is currently limited to investigational use. Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer and was incubated at the MEDX Xelerator (now EdgeLabs); it operates within the Edge Medical Ventures portfolio with operations in the U.S. and Israel. Following an $11 million seed financing, the company plans to use proceeds for clinical validation, product and manufacturing development, initial U.S. commercialization efforts, and establishment of its Jersey City headquarters.

Participated · Seed · Oct 2025

CustoMED’s cloud platform converts a surgeon’s pre-operative plan and medical imaging into customized surgical tools and implants within minutes, integrating seamlessly into existing workflows. By combining artificial intelligence, automation, and 3D printing, the system aims to reduce intraoperative errors and deliver more predictable outcomes while leaving surgeons in full clinical control. The technology has already been deployed in hundreds of surgeries worldwide, with thousands more slated for the coming year. Originating in Sheba Medical Center’s 3D Printing & Innovation Lab, the company was co-founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi and operates within Sheba’s ARC Innovation ecosystem in Ramat Gan. CustoMED plans to use new capital to expand into additional orthopedic indications, pursue U.S. and EU regulatory clearances expected in 2026, and scale its on-demand manufacturing model globally. To date, the company has raised $6 million in funding.

Participated · Seed · Jun 2025

Lembas has built a proprietary computational AI discovery platform that rapidly screens, analyzes and designs food-grade bioactive peptides, with an initial product called GLP-1 Edge designed to enhance the body's own GLP-1 response. GLP-1 Edge has been demonstrated in cell and animal models to stimulate GLP-1 secretion to blood and is shown in multiple consumer formats including gummies, powder, and capsules. The company positions the ingredient for integration into bars, shakes, snacks, beverages and supplements to address the global weight management market. Lembas emphasizes food-as-medicine applications and plans to scale commercialization and deepen commercial agreements across the ingredients, food and supplements value chain. Backed by university-patented pending technology, the team combines entrepreneurs and interdisciplinary scientists with executive experience from leading food companies. Founded in 2024 and based in Tel Aviv, Israel, Lembas emerged from stealth following its early validation.

Participated · Seed · Mar 2025

Faireez provides an AI-powered housekeeping platform that pairs dedicated building housekeepers—called “fairies”—with technology to deliver consistent, hotel-quality service to multifamily residents. The company operates a subscription model that assigns a designated fairy to each building and enables short daily visits focused on specific chores rather than infrequent deep cleans. Its proprietary AI features include an upcoming "auto scan" video analysis to generate tailored cleaning plans and an AI quality-assurance system that analyzes time-stamped before-and-after photos and sends real-time notifications. Faireez also combines human staff with robotic companions and teleoperations, allowing professional housekeepers in locations such as Mexico to remotely assist or operate robots in U.S. homes. The platform emphasizes transparency and customization through mobile app controls and documented visits. Faireez has formed partnerships with property managers and landlords including Silverstein Properties, First Service Residential, BNE, Ironstate and Charney Companies, and launched from stealth with $7.5M in funding as it targets servicing one million multifamily units by 2030.

Led · Seed · Feb 2025

Exero Medical's flagship product, the xBar system, uses sensors placed at the surgical site to collect tissue-healing data that can help clinicians detect major, life-threatening post-operative complications earlier. The xBar has received FDA Breakthrough Device Designation and is currently limited to investigational use in the United States. The company plans to complete an FDA pivotal trial and launch the xBar system in the U.S.; it has established a new U.S. headquarters at Scitech Scity at the Liberty Science Center in Jersey City, NJ to support clinical and commercial activities. Exero was founded in 2018 by MEDX Xelerator and is backed by public- and private-sector supporters named in the company's materials. Financially, Exero has secured financing to advance its regulatory program and U.S. expansion. The company emphasizes improving patient outcomes and reducing costs by adding new postoperative health data into clinical workflows.